DK1888024T4 - Topiske sammensætninger - Google Patents
Topiske sammensætninger Download PDFInfo
- Publication number
- DK1888024T4 DK1888024T4 DK06728329.1T DK06728329T DK1888024T4 DK 1888024 T4 DK1888024 T4 DK 1888024T4 DK 06728329 T DK06728329 T DK 06728329T DK 1888024 T4 DK1888024 T4 DK 1888024T4
- Authority
- DK
- Denmark
- Prior art keywords
- skin
- topical pharmaceutical
- topical
- pharmaceutical composition
- products
- Prior art date
Links
- 230000000699 topical effect Effects 0.000 title claims description 20
- 239000000203 mixture Substances 0.000 title claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 11
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 7
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 210000004927 skin cell Anatomy 0.000 claims description 6
- 239000000811 xylitol Substances 0.000 claims description 6
- 235000010447 xylitol Nutrition 0.000 claims description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 6
- 229960002675 xylitol Drugs 0.000 claims description 6
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 5
- 229960000367 inositol Drugs 0.000 claims description 5
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 229960001855 mannitol Drugs 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 230000005779 cell damage Effects 0.000 claims description 3
- 208000037887 cell injury Diseases 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 description 23
- 230000007794 irritation Effects 0.000 description 15
- 239000000126 substance Substances 0.000 description 13
- 230000003020 moisturizing effect Effects 0.000 description 9
- 239000006196 drop Substances 0.000 description 8
- 239000003599 detergent Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000000622 irritating effect Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 5
- 239000002085 irritant Substances 0.000 description 5
- 231100000021 irritant Toxicity 0.000 description 5
- 239000006210 lotion Substances 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000000254 damaging effect Effects 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940025703 topical product Drugs 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- -1 conditioners Substances 0.000 description 2
- 239000002781 deodorant agent Substances 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000000077 insect repellent Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 241000021559 Dicerandra Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229940125695 gastrointestinal agent Drugs 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000003009 skin protective agent Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (6)
1. Topisk farmaceutisk sammensætning til anvendelse i forebyggelsen og behandlingen af irriterede hudceller, omfattende en kombination af: 5 -18% xylitol, myoinositol eller mannitol eller enhver kombination af disse; 5 -10% glycerol og/eller urea; og, vand; i fraværet af en hvilken som helst olie i vand eller voks i vand emulsion.
2. Topisk farmaceutisk sammensætning til anvendelse ifølge krav 1, yderligere indeholdende mindst et viskositetsforøgende middel.
3. Topisk farmaceutisk sammensætning til anvendelse ifølge krav 2, hvori nævnte viskositetsforøgende middel består af en polymer med en molekylmasse lig med mere end 0,5 millioner Dalton.
4. Topisk farmaceutisk sammensætning til anvendelse ifølge krav 1, hvori nævnte sammensætnings pH er imellem 4,0 og 6,0.
5. Topisk farmaceutisk sammensætning til anvendelse ifølge krav 1, nyttig til forebyggelsen og lindringen af celleskade, der er forårsaget af konserveringsmidler, rensemidler eller medikamenter, der er anvendt i topisk farmaceutisk kosmetiske eller veterinære sammensætninger.
6. Topisk farmaceutisk sammensætning til anvendelse ifølge krav 1, yderligere indeholdende et overfladeaktivt middel.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL168603A IL168603A (en) | 2005-05-16 | 2005-05-16 | Pharmaceutical or cosmetic composition for the prevention and treatment of irritation of mucous cells or skin cells |
| PCT/IL2006/000537 WO2006123324A1 (en) | 2005-05-16 | 2006-05-07 | Topical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK1888024T3 DK1888024T3 (da) | 2012-11-26 |
| DK1888024T4 true DK1888024T4 (da) | 2015-10-26 |
Family
ID=36952425
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12159243.0T DK2465493T3 (da) | 2005-05-16 | 2006-05-07 | Topiske sammensætninger til forebyggelsen og behandlingen af irritation af mukøse celler |
| DK06728329.1T DK1888024T4 (da) | 2005-05-16 | 2006-05-07 | Topiske sammensætninger |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12159243.0T DK2465493T3 (da) | 2005-05-16 | 2006-05-07 | Topiske sammensætninger til forebyggelsen og behandlingen af irritation af mukøse celler |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20080207771A1 (da) |
| EP (2) | EP2465493B1 (da) |
| DK (2) | DK2465493T3 (da) |
| ES (2) | ES2393927T5 (da) |
| IL (1) | IL168603A (da) |
| PL (2) | PL1888024T3 (da) |
| PT (2) | PT1888024E (da) |
| WO (1) | WO2006123324A1 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10183076B2 (en) | 2005-05-16 | 2019-01-22 | Resdevco Research And Development Co. L | Topical compositions for treatment of irritation of mucous membranes |
| US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US20090131386A1 (en) * | 2007-11-13 | 2009-05-21 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| US20100216754A1 (en) * | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| DK3354276T3 (da) | 2007-11-13 | 2020-03-30 | Meritage Pharma Inc | Sammensætninger til behandlingen af gastrointestinal inflammation |
| US20090264392A1 (en) * | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
| EP2363126A1 (en) * | 2010-03-04 | 2011-09-07 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Composition comprising as active ingredient L-carnitine in combination with hydroxykynurenine-O-beta-DL-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation |
| CN103327965B (zh) | 2011-01-25 | 2017-07-18 | 宝洁公司 | 脂质体和包含脂质体的个人护理组合物 |
| IL212725A (en) | 2011-05-05 | 2016-06-30 | Resdevco Res And Dev Co | Glycerol Preparation for Non-surgical Conjunctivochalysis |
| US9511144B2 (en) | 2013-03-14 | 2016-12-06 | The Proctor & Gamble Company | Cosmetic compositions and methods providing enhanced penetration of skin care actives |
| KR20160110956A (ko) * | 2014-01-28 | 2016-09-23 | 레스데브코 리서치 앤드 디벨롭먼트 컴파니 리미티드 | 피부 및 점막의 국소 치료를 위한 자일리톨 및 콜레칼시페롤을 포함하는 조성물 |
| ITUB20153104A1 (it) * | 2015-08-13 | 2017-02-13 | Sooft Italia S P A Contrada Molino 17 68333 Montegiorgio Fm | Composizione ed uso di collirio a base di inositolo per migliorare l'accomodazione visiva dei pazienti |
| AU2018230262B2 (en) * | 2017-03-05 | 2024-01-18 | Resdevco Research And Development Co. Ltd. | Eye drops for treatment of irritation not due to infection |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL80298A (en) † | 1986-10-14 | 1993-01-31 | Res & Dev Co Ltd | Eye drops |
| JPS63270625A (ja) * | 1987-04-30 | 1988-11-08 | Santen Pharmaceut Co Ltd | 抗アレルギ−点眼剤 |
| JPH0278619A (ja) * | 1988-09-12 | 1990-03-19 | Santen Pharmaceut Co Ltd | 安定なピレノキシン点眼液 |
| US6294520B1 (en) * | 1989-03-27 | 2001-09-25 | Albert T. Naito | Material for passage through the blood-brain barrier |
| US5089255A (en) * | 1989-06-26 | 1992-02-18 | Colgate-Palmolive Company | Dental remineralization |
| DE4229494A1 (de) * | 1992-09-04 | 1994-03-10 | Basotherm Gmbh | Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks |
| DE4312656C2 (de) * | 1993-04-19 | 1996-01-25 | Beiersdorf Ag | Kühlend wirkende kosmetische oder dermatologische Zusammensetzungen |
| GB9313329D0 (en) * | 1993-06-28 | 1993-08-11 | Scherer Ltd R P | Softgel capsule shell compositions |
| TW274516B (da) * | 1993-11-12 | 1996-04-21 | Ciba Geigy Ag | |
| US5866536A (en) * | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| CZ295460B6 (cs) * | 1997-03-20 | 2005-08-17 | Schering Corporation | Způsob výroby aglomerátů a jednotková dávka farmakologicky aktivní látky je obsahující |
| EP0909558A3 (en) * | 1997-08-29 | 1999-10-27 | Santen Pharmaceutical Co., Ltd. | Chroman derivative containing ophthalmic solution |
| FI974385A0 (fi) * | 1997-12-01 | 1997-12-01 | Xyrofin Oy | Anvaendning av xylitol foer bekaempning av jaestinfektion och xylitolpreparat foer denna anvaendning |
| US6238648B1 (en) † | 1999-03-25 | 2001-05-29 | The Procter & Gamble Company | Anti-caries oral care compositions and their methods of use |
| GB9928055D0 (en) † | 1999-11-26 | 2000-01-26 | Alcan Int Ltd | Oral cleansing product |
| US6361806B1 (en) * | 2000-02-23 | 2002-03-26 | Michael P. Allen | Composition for and method of topical administration to effect changes in subcutaneous adipose tissue |
| US6716819B2 (en) * | 2000-05-19 | 2004-04-06 | University Of Iowa Research Foundation | Use of xylitol to reduce ionic strength and activate endogenous antimicrobials for prevention and treatment of infections |
| AR035509A1 (es) * | 2000-12-21 | 2004-06-02 | Alcon Inc | Solucion de lagrimas artificiales mejorada que contiene una combinacion de tres emolientes y el uso de dicha solucion para la fabricacion de un medicamento |
| WO2002053127A1 (en) | 2000-12-28 | 2002-07-11 | Shiseido Company, Ltd. | Agents for inhibiting or restoring skin damage caused by drying and method of evaluating the same |
| JP4229422B2 (ja) | 2001-07-04 | 2009-02-25 | 河野製紙株式会社 | 繊維ウェブ製品 |
| ES2186569B1 (es) † | 2001-09-28 | 2004-09-16 | Lacer, S.A. | Composiciones para el alivio de la xerostomia y el tratamiento de los trastornos asociados con la misma. |
| WO2003051316A1 (en) * | 2001-12-18 | 2003-06-26 | John Kanca, Iii | Device for dental applications |
| US6890961B2 (en) † | 2002-02-01 | 2005-05-10 | Micelle Products, Inc. | Clear micellized formulations of β-carotene and method of treating leukoplakia |
| US6482830B1 (en) * | 2002-02-21 | 2002-11-19 | Supergen, Inc. | Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor |
| CA2481394A1 (en) * | 2002-05-24 | 2003-12-04 | Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh | Drop-forming ophthalmic gel preparation comprising diclofenamide and timolol |
| US20040191332A1 (en) * | 2003-03-27 | 2004-09-30 | Allergan, Inc. | Preserved ophthalmic compositions |
| JP3797431B2 (ja) † | 2003-09-08 | 2006-07-19 | ライオン株式会社 | 口腔用組成物及びその製造方法 |
-
2005
- 2005-05-16 IL IL168603A patent/IL168603A/en active IP Right Grant
-
2006
- 2006-05-07 PL PL06728329T patent/PL1888024T3/pl unknown
- 2006-05-07 PT PT67283291T patent/PT1888024E/pt unknown
- 2006-05-07 DK DK12159243.0T patent/DK2465493T3/da active
- 2006-05-07 EP EP12159243.0A patent/EP2465493B1/en active Active
- 2006-05-07 US US11/914,429 patent/US20080207771A1/en not_active Abandoned
- 2006-05-07 DK DK06728329.1T patent/DK1888024T4/da active
- 2006-05-07 ES ES06728329.1T patent/ES2393927T5/es active Active
- 2006-05-07 WO PCT/IL2006/000537 patent/WO2006123324A1/en not_active Ceased
- 2006-05-07 PT PT121592430T patent/PT2465493E/pt unknown
- 2006-05-07 EP EP06728329.1A patent/EP1888024B2/en active Active
- 2006-05-07 ES ES12159243T patent/ES2433271T3/es active Active
- 2006-05-07 PL PL12159243T patent/PL2465493T3/pl unknown
-
2017
- 2017-08-28 US US15/687,600 patent/US10660961B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT1888024E (pt) | 2012-12-04 |
| EP1888024B1 (en) | 2012-08-29 |
| EP1888024B2 (en) | 2015-07-15 |
| PL1888024T3 (pl) | 2013-02-28 |
| ES2393927T3 (es) | 2013-01-02 |
| US20080207771A1 (en) | 2008-08-28 |
| IL168603A (en) | 2011-05-31 |
| ES2393927T5 (es) | 2015-12-21 |
| ES2433271T3 (es) | 2013-12-10 |
| PL2465493T3 (pl) | 2013-12-31 |
| EP2465493B1 (en) | 2013-08-07 |
| PT2465493E (pt) | 2013-11-11 |
| DK2465493T3 (da) | 2013-10-28 |
| EP2465493A1 (en) | 2012-06-20 |
| US10660961B2 (en) | 2020-05-26 |
| EP1888024A1 (en) | 2008-02-20 |
| US20170354735A1 (en) | 2017-12-14 |
| DK1888024T3 (da) | 2012-11-26 |
| WO2006123324A1 (en) | 2006-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10660961B2 (en) | Method of treatment of irritation of skin or mucous cells | |
| US10183076B2 (en) | Topical compositions for treatment of irritation of mucous membranes | |
| CA1157380A (en) | Preparations containing methylsulfonylmethane and methods of use and purification | |
| US4863725A (en) | Novel clear oil-free moisturizer composition | |
| JP4133837B2 (ja) | 皮膚保湿用ゲルおよび方法 | |
| US20080254150A1 (en) | Management of dermatitic symptoms of mammalian integument with emollient disinfectant formulations | |
| EP0806947A1 (en) | Formulations and methods for reducing skin irritation | |
| WO2012126140A1 (zh) | 逆向温敏可逆水凝胶组合物 | |
| WO1996023490A9 (en) | Formulations and methods for reducing skin irritation | |
| CN103816165A (zh) | 一种治疗痤疮的组合物 | |
| JPH0873342A (ja) | 覆盆子抽出物含有皮膚外用剤または浴用剤 | |
| JP2002226386A (ja) | 植物抽出物を含有する外皮用組成物 | |
| JP2005524651A (ja) | にきびの治療のための局所用ダプソン | |
| JP3962666B2 (ja) | 皮膚外用剤 | |
| JPH1017430A (ja) | 刺激防御剤及びそれを含有する刺激防御用の化粧料 | |
| JPH09268119A (ja) | 皮膚外用剤 | |
| JP3479048B2 (ja) | 化粧料及び不織布含浸化粧料 | |
| JPH06279231A (ja) | 化粧料 | |
| US20170354624A1 (en) | Topical compositions for treatment of skin irritation | |
| RU2792212C1 (ru) | Композиция для защиты кожи от воздействия вредных веществ, света и стресса | |
| JP3516792B2 (ja) | 皮膚外用剤 | |
| JP2001226251A (ja) | 皮膚用外用組成物 | |
| WO2006121210A1 (ja) | 皮膚状態改善剤 | |
| JP2826141B2 (ja) | フケ抑制剤組成物 | |
| KR20040043596A (ko) | 셀룰로스를 유효성분으로 함유하는 항각질 조성물 |